Orrenzo Snyder, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Boston Scientific at 50.0% of the total. Reporting peaked in 2019 at $9,926 and has fallen 90.5% since, to $942 in 2025.
Across 121 payments — averaging $133.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- Coloplast$3K
- Intuitive Surgical$2K
- Medtronic$1K
- Astellas Pharma US Inc$328
- Johnson & Johnson$282
- plus $874 from 15 others
What the payments were for
- Speaking & faculty fees$7,00043%
- Travel & lodging$5,33033%
- Food & beverage$3,55222%
- Education$2712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $8,081 |
| Coloplast | 18 | $3,221 |
| Intuitive Surgical | 9 | $1,964 |
| Medtronic | 16 | $1,404 |
| Astellas Pharma US Inc | 12 | $328 |
| Johnson & Johnson | 8 | $282 |
| Teleflex LLC | 4 | $192 |
| Myriad Genetic Laboratories, Inc. | 9 | $177 |
| Endo USA, Inc. | 4 | $83 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Ferring Pharmaceuticals Inc. | 3 | $68 |
| Progenics Pharmaceuticals, Inc. | 2 | $43 |
| Urogen Pharma, Inc. | 1 | $38 |
| Blue Earth Diagnostics | 1 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Cook Medical LLC | 1 | $28 |
| Urovant Sciences Inc | 1 | $27 |
| Neotract Inc. | 1 | $22 |
| Pfizer | 1 | $19 |
| Merck | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GREENLIGHT$7,333
- ALTIS$2,072
- Da Vinci Surgical System$1,611
- AXIS$845
- INTERSTIM$467
- DA VINCI SP$245
- GENERAL ERECTILE DYSFUNCTION$221
- Erleada$118
- UroLift$117
- LITHOCLAST$100
How this compares
$16,154 in reported general payments places this provider in the 85th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 12 | $7,353 |
| Tamsulosin Hcl | 70 | $1,153 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $1,142 |
| Oxybutynin Chloride ErOxybutynin Chloride | 50 | $1,118 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $436 |
| Solifenacin Succinate | 19 | $220 |
| Finasteride | 17 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $7,35312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 269 urology providers in Arizona.
Other urology in Page
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
- Rahul MehanMesa$277K
- Mitzi BarmatzTucson$135K
- Chinedu MmejeGilbert$114K
- John LinGilbert$108K
- Donald LammPhoenix$80K
- Michael ZellScottsdale$64K
- Aaron LatowskyLitchfield Park$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.